• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lifezone Metals launches off-take marketing process for nickel, copper and cobalt from the Kabanga nickel project

    4/19/23 7:38:00 AM ET
    $GOGN
    $OGN
    Blank Checks
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GOGN alert in real time by email

    LONDON, April 19, 2023 /PRNewswire/ -- Lifezone Holdings Limited ("Lifezone Metals") has previously announced entry into a Business Combination Agreement with GoGreen Investments Corporation (NYSE:GOGN), a publicly traded company on the NYSE ("GoGreen"). Today, Lifezone Metals is pleased to announce that it has commenced an off-take marketing process with respect to the nickel, copper and cobalt from the Kabanga nickel project (the "Kabanga Project"), which Lifezone Metals believes comprises one of the world's largest and highest-grade nickel sulfide deposits.

    Lifezone Metals Logo

    Lifezone Metals seeks to support the clean energy transition through licensing of its proprietary hydromet mineral processing technology (the "Hydromet Technology") as an alternative to smelting in metals production and becoming an emerging supplier of responsibly-sourced, low-carbon and low-sulfur dioxide emission metals to the battery, electric vehicle ("EV") and hydrogen markets. Lifezone Metals is entitled to certain off-take marketing rights with respect to the Kabanga Project and has retained the marketing rights for up to 40%, in aggregate, of the total contained nickel, cobalt and copper production from the Kabanga Project.

    Given the interest in these products from original equipment manufacturers, the company has commenced a process aimed at monetising the off-take from the Kabanga Project. RBC Capital Markets has been engaged to run a formal off-take marketing process. Further updates on the process will be provided as appropriate.

    Chris Showalter, CEO of Lifezone Metals, said: "The commencement of the off-take marketing process for the nickel, cobalt and copper to be produced at the Kabanga Project  is a key milestone in the development of Lifezone Metals, as we work to build a champion for cleaner metals to support the global energy transition.

    There is a clear focus on upstream environmental footprint driven by consumer demand and regulatory targets in the US and Europe, and we expect a shift away from heavy-polluting sources of raw materials into the battery and EV supply chain. Recent test results indicate that the Kabanga Project's nickel concentrate is amenable to processing using the Hydromet Technology, which we believe is key to unlocking the value of the project and paving the way for our future cleaner metal products."

    About Lifezone Metals 

    Lifezone Metals is a modern metals company creating value across the battery metals supply chain from resource to metals production and recycling. Our mission is to provide commercial access to proprietory technology and cleaner metals production through a scalable platform underpinned by our tailored hydromet technology. This technology has the potential to be a cleaner and lower cost alternative to smelting, allowing us to responsibly and cost-effectively provide cleaner metals.

    By pairing Tanzania's Kabanga Project, which we believe is one of the largest and highest-grade undeveloped nickel sulphide deposits in the world, with our proprietary hydromet technology, we will work to unlock the value of a key new source of supply to global battery metals markets. We partner with BHP on the Kabanga Project as we aim to empower Tanzania to achieve full value in-country and become the next premier source of nickel.

    www.lifezonemetals.com 

    Business Combination with GoGreen Investments Corporation

    Lifezone Metals announced on December 13, 2022 a business combination agreement with GoGreen Investments Corporation (NYSE:GOGN). The business combination between Lifezone Metals and GoGreen Investments Corporation is subject to customary closing conditions.

    About GoGreen Investments Corporation

    GoGreen Investments Corporation is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. GoGreen is led by Chief Executive Officer John Dowd.

    www.gogreeninvestments.com

    Contacts

    Lifezone Metals

    Natasha Liddell

    Executive Vice President ESG & Communications

    [email protected]   

    Media Enquiries

    Tom Batchelar

    TAB Communications

    [email protected] 

    +44 (0) 7814 964 287

    Daniel Thole

    Fletcher Advisory

    [email protected]

    +44 (0) 7821 571 308

    Forward-Looking Statements

    Certain statements made herein are not historical facts but may be considered "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" or the negatives of these terms or variations of them or similar terminology or expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, the proposed business combination between GoGreen and Lifezone Metals, the estimated or anticipated future results and benefits of the combined company following the business combination, including the likelihood and ability of the parties to successfully consummate the business combination, future opportunities for the combined company, including the efficacy of the Hydromet Technology and the development of, and processing of mineral resources at, the Kabanga Project, and other statements that are not historical facts.

    These statements are based on the current expectations of GoGreen and/or Lifezone Metals' management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of GoGreen and Lifezone Metals. These statements are subject to a number of risks and uncertainties regarding Lifezone Metals' business and the business combination, and actual results may differ materially. These risks and uncertainties include, but are not limited to: general economic, political and business conditions, including but not limited to the economic and operational disruptions and other effects of the COVID-19 pandemic; the inability of the parties to consummate the business combination or the occurrence of any event, change or other circumstances that could give rise to the termination of the business combination agreement; the number of redemption requests made by GoGreen's shareholders in connection with the business combination; the outcome of any legal proceedings that may be instituted against the parties following the announcement of the business combination; the risk that the approval of the shareholders of Lifezone Metals or GoGreen for the potential transaction is not obtained; failure to realize the anticipated benefits of the business combination, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of Lifezone Metals and GoGreen; the risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the business combination; the risks related to the rollout of Lifezone Metals' business, the efficacy of the Hydromet Technology, and the timing of expected business milestones; Lifezone Metals' development of, and processing of mineral resources at, the Kabanga Project; the effects of competition on Lifezone Metals' business; the ability of the combined company to execute its growth strategy, manage growth profitably and retain its key employees; the ability of Lifezone Metals Limited ("Holdings") to obtain or maintain the listing of its securities on a U.S. national securities exchange following the business combination; costs related to the business combination; and other risks that will be detailed from time to time in filings with the U.S. Securities and Exchange Commission (the "SEC"). The foregoing list of risk factors is not exhaustive. There may be additional risks that Lifezone Metals presently does not know or that Lifezone Metals currently believes are immaterial that could also cause actual results to differ from those contained in forward-looking statements. In addition, forward-looking statements provide Lifezone Metals' expectations, plans or forecasts of future events and views as of the date of this communication. Lifezone Metals anticipates that subsequent events and developments will cause Lifezone Metals' assessments to change. However, while Lifezone Metals may elect to update these forward-looking statements in the future, Lifezone Metals specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Lifezone Metals' assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements. Nothing herein should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or results of such forward-looking statements will be achieved.

    Certain statements made herein include references to "clean" or "green" metals, methods of production of such metals, energy or the future in general. Such references relate to environmental benefits such as lower green-house gas ("GHG") emissions and energy consumption involved in the production of metals using the Hydromet Technology relative to the use of traditional methods of production and the use of metals such as nickel in the batteries used in electric vehicles. While studies by third parties (commissioned by Lifezone Metals) have shown that the Hydromet Technology, under certain conditions, results in lower GHG emissions and lower consumption of electricity compared to smelting with respect to refining platinum group metals, no active refinery currently licenses Lifezone Metals' Hydromet Technology. Accordingly, Lifezone Metals' Hydromet Technology and the resultant metals may not achieve the environmental benefits to the extent Lifezone Metals expects or at all. Any overstatement of the environmental benefits in this regard may have adverse implications for Lifezone Metals and its stakeholders.

    Additional Information and Where to Find It

    In connection with the business combination, Holdings filed a registration statement on Form F-4 (File No. 333-271300) (as amended, the "Registration Statement") with the SEC, which includes a preliminary prospectus and preliminary proxy statement and, after the Registration Statement is declared effective, GoGreen will mail a definitive proxy statement/prospectus and other relevant documents relating to the business combination to its shareholders. This communication is not a substitute for the Registration Statement, the definitive proxy statement/prospectus or any other document that GoGreen will send to its shareholders in connection with the business combination.

    INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS, ALL AMENDMENTS THERETO, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION AND THE PARTIES TO THE BUSINESS COMBINATION.  Investors and security holders will be able to obtain copies of these documents (if and when available) and other documents filed with the SEC free of charge at www.sec.gov. The definitive proxy statement/final prospectus (if and when available) will be mailed to shareholders of GoGreen as of a record date to be established for voting on the business combination. Shareholders of GoGreen will also be able to obtain copies of the proxy statement/prospectus without charge, once available, at the SEC's website at www.sec.gov, or by directing a request to: GoGreen Investments Corporation, One City Centre, 1021 Main Street, Suite 1960, Houston, TX 77002.

    Participants in the Solicitation

    Holdings, Lifezone Metals, GoGreen and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed participants in the solicitation of proxies of GoGreen's shareholders in connection with the business combination. Investors and security holders may obtain more detailed information regarding the names and interests in the business combination of the directors and officers of Holdings, Lifezone Metals, GoGreen in the Registration Statement. Information about GoGreen's directors and executive officers is also available in GoGreen's filings with the SEC.

    No Offer or Solicitation

    This communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote in any jurisdiction pursuant to the business combination or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

    Logo: https://mma.prnewswire.com/media/2010304/Lifezone_Metals_Logo.jpg

    Cision View original content:https://www.prnewswire.com/news-releases/lifezone-metals-launches-off-take-marketing-process-for-nickel-copper-and-cobalt-from-the-kabanga-nickel-project-301801736.html

    SOURCE Lifezone Metals

    Get the next $GOGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GOGN
    $OGN

    CompanyDatePrice TargetRatingAnalyst
    Organon & Co.
    $OGN
    12/9/2025$7.50Underweight
    Barclays
    Organon & Co.
    $OGN
    10/27/2025$5.00Overweight → Underweight
    Piper Sandler
    Organon & Co.
    $OGN
    5/2/2025Outperform → In-line
    Evercore ISI
    Organon & Co.
    $OGN
    9/6/2024$18.00 → $20.00Neutral → Underweight
    JP Morgan
    Organon & Co.
    $OGN
    11/3/2023$33.00 → $16.00Buy → Neutral
    Goldman
    Organon & Co.
    $OGN
    9/21/2023$28.00Overweight
    Barclays
    Organon & Co.
    $OGN
    3/16/2023$33.00Outperform
    Raymond James
    Organon & Co.
    $OGN
    10/14/2022$27.00 → $25.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $GOGN
    $OGN
    SEC Filings

    View All

    Organon & Co. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Organon & Co. (0001821825) (Filer)

    2/20/26 7:30:42 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon & Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Organon & Co. (0001821825) (Filer)

    2/12/26 7:45:44 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Organon & Co.

    10-Q - Organon & Co. (0001821825) (Filer)

    11/10/25 8:08:29 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOGN
    $OGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Organon with a new price target

    Barclays initiated coverage of Organon with a rating of Underweight and set a new price target of $7.50

    12/9/25 8:51:54 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Organon from Overweight to Underweight and set a new price target of $5.00

    10/27/25 11:23:41 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon downgraded by Evercore ISI

    Evercore ISI downgraded Organon from Outperform to In-line

    5/2/25 8:13:50 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOGN
    $OGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chair Cox Carrie Smith bought $501,755 worth of shares (65,400 units at $7.67) (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    11/13/25 4:05:10 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Cox Carrie Smith bought $100,591 worth of shares (12,469 units at $8.07) (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    5/15/25 4:09:09 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Human Resources Officer Falcione Aaron bought $48,235 worth of shares (5,500 units at $8.77), increasing direct ownership by 10% to 62,974 units (SEC Form 4)

    4 - Organon & Co. (0001821825) (Issuer)

    5/7/25 12:13:47 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOGN
    $OGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Interim Head of Mfg & Supply Drinane Juliana Papa covered exercise/tax liability with 1,242 shares, decreasing direct ownership by 7% to 17,175 units (SEC Form 4)

    4/A - Organon & Co. (0001821825) (Issuer)

    1/16/26 4:37:45 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Interim Head of Mfg & Supply Drinane Juliana Papa

    4 - Organon & Co. (0001821825) (Issuer)

    11/17/25 4:05:02 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Interim CEO Morrissey Joseph T. Jr.

    4 - Organon & Co. (0001821825) (Issuer)

    11/17/25 4:04:18 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOGN
    $OGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight

    The atopic dermatitis market is expected to grow, driven by the extensive market penetration of approved therapies for moderate-to-severe atopic dermatitis and the entry of new therapies such as OX40 inhibitor (Rocatinlimab [KHK4083/AMG451]), OX40L inhibitor (Amlitelimab [KY1005]), PDE4 inhibitor (Orismilast), TSLP inhibitor (Bosakitug [BSI-045B]), IL-22RA1 blocker (Temtokibart [LP0145; LEO 138559]), IL-4Rα blocker (Rademikibart [CBP-201]), and others.LAS VEGAS, Feb. 16, 2026 /PRNewswire/ -- Recently published Atopic Dermatitis Market Insights report includes a comprehensive understanding of current treatment practices, atopic dermatitis emerging drugs, market share of individual therapies,

    2/16/26 5:31:00 PM ET
    $ABBV
    $AMGN
    $APGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Commercial Physical & Biological Resarch

    Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

    Full year 2025 revenue of $6.2 billion, down 3% on both an as-reported basis and at constant currency Full year 2025 diluted earnings per share of $0.72 and non-GAAP Adjusted diluted earnings per share of $3.66 Full year 2025 Adjusted EBITDA of $1.91 billion inclusive of $6 million of IPR&D, representing a 30.7% Adjusted EBITDA margin The company expects to deliver approximately $6.2 billion of revenue and approximately $1.9 billion of Adjusted EBITDA for the full year 2026, both measures in-line with full year 2025 performance. Organon (NYSE:OGN) today announced its results for the fourth quarter and full year ended December 31, 2025. "In 2025 we took action that demonstrate

    2/12/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

    Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its fourth quarter and full year 2025 financial results on February 12, 2026, prior to the company's webcast and conference call scheduled for 8:30 a.m. ET. IPR&D and Milestones Organon does not currently expect to record any milestone expense in the fourth quarter of 2025. Organon's fourth quarter and full year 2025 results have not been finalized and are subject to the company's quarterly financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimates described herein. Accessing Fourth Quarter and Full Year 2025 F

    1/29/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOGN
    $OGN
    Leadership Updates

    Live Leadership Updates

    View All

    Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

    Organon (NYSE:OGN) ("Organon" or "the company") today announced that its Board of Directors has appointed the Company's Executive Vice President and Head of Manufacturing & Supply, Joseph Morrissey, Interim Chief Executive Officer. Board Chair Carrie S. Cox will also take on additional responsibilities on an interim basis as Executive Chair to support Mr. Morrissey in his new role. Director Robert Essner will assume the role of Lead Independent Director. These appointments follow the resignation of Kevin Ali as Chief Executive Officer and member of the Board in connection with the Audit Committee investigation described below. Mr. Ali has agreed that he will not be entitled to severance o

    10/27/25 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon Appoints Ramona A. Sequeira to the Company's Board of Directors

    Organon (NYSE:OGN) a global healthcare company with a focus on women's health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organon's Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Board's Talent Committee. In connection with Ms. Sequeira's appointment, the size of Organon's Board will be expanded to 12 directors. Ms. Sequeira brings more than 30 years of pharmaceutical industry expertise, with 20 years at Eli Lilly and Company and 10 years at Takeda. She is a proven commercial leader with a steadfast commitment to building strategies around the needs of patients and a trac

    4/15/25 5:00:00 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAY HEALTH APPOINTS SEASONED MEDTECH EXECUTIVE, COLBY HOLTSHOUSE, AS PRESIDENT AND CEO

    Leadership transition comes as Company focuses on clinical evaluation of its novel Ovarian Rebalancing™ technology, a one-time transvaginal ablation procedure designed to restore ovulation in women with PCOS, a leading cause of infertility PARIS, March 10, 2025 /PRNewswire/ -- May Health, a Paris- and California-based, clinical-stage medical device company dedicated to the development of a new treatment for Polycystic Ovary Syndrome (PCOS), today announced that Colby Holtshouse has joined the Company as President and CEO. Colby brings a wealth of senior leadership and women's health expertise to the organization, having held executive positions with Organon (NYSE:OGN), Alydia Health, and Pel

    3/10/25 12:01:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOGN
    $OGN
    Financials

    Live finance-specific insights

    View All

    Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

    Full year 2025 revenue of $6.2 billion, down 3% on both an as-reported basis and at constant currency Full year 2025 diluted earnings per share of $0.72 and non-GAAP Adjusted diluted earnings per share of $3.66 Full year 2025 Adjusted EBITDA of $1.91 billion inclusive of $6 million of IPR&D, representing a 30.7% Adjusted EBITDA margin The company expects to deliver approximately $6.2 billion of revenue and approximately $1.9 billion of Adjusted EBITDA for the full year 2026, both measures in-line with full year 2025 performance. Organon (NYSE:OGN) today announced its results for the fourth quarter and full year ended December 31, 2025. "In 2025 we took action that demonstrate

    2/12/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

    Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its fourth quarter and full year 2025 financial results on February 12, 2026, prior to the company's webcast and conference call scheduled for 8:30 a.m. ET. IPR&D and Milestones Organon does not currently expect to record any milestone expense in the fourth quarter of 2025. Organon's fourth quarter and full year 2025 results have not been finalized and are subject to the company's quarterly financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimates described herein. Accessing Fourth Quarter and Full Year 2025 F

    1/29/26 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organon Reports Results for the Third Quarter Ended September 30, 2025

    Third quarter 2025 revenue of $1.602 billion, up 1% as-reported and down 1% excluding the impact of foreign currency Third quarter 2025 diluted earnings per share of $0.61 and non-GAAP Adjusted diluted earnings per share of $1.01 Third quarter 2025 net income of $160 million and Adjusted EBITDA (non-GAAP) of $518 million, representing an Adjusted EBITDA margin of 32.3% Revenue guidance range for full year 2025 lowered to $6.200 billion to $6.250 billion; Adjusted EBITDA margin guidance lowered to ~31.0% Organon (NYSE:OGN) today announced its results for the third quarter ended September 30, 2025. "I am humbled to be working alongside our talented team during this pivotal time

    11/10/25 7:30:00 AM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GOGN
    $OGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Organon & Co. (Amendment)

    SC 13G/A - Organon & Co. (0001821825) (Subject)

    2/13/24 5:12:22 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by GoGreen Investments Corporation (Amendment)

    SC 13G/A - GoGreen Investments Corp (0001852940) (Subject)

    2/9/24 6:16:37 AM ET
    $GOGN
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Organon & Co. (Amendment)

    SC 13G/A - Organon & Co. (0001821825) (Subject)

    2/5/24 3:47:19 PM ET
    $OGN
    Biotechnology: Pharmaceutical Preparations
    Health Care